Date Filed | Type | Description |
10/03/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 10% stake in Soleno Therapeutics, Inc. |
08/18/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
08/18/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 12.3% stake in Soleno Therapeutics, Inc. |
08/04/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/02/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 4.2% stake in Vera Therapeutics, Inc. |
08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/01/2023 |
8-K
| Quarterly results |
07/17/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 8.1% stake in Carlyle Credit Income Fund |
07/05/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 5.5% stake in Vera Therapeutics, Inc. |
06/16/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
06/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
05/10/2023 |
SC 13D/A
| Carlyle Group Inc. has filed a Schedule 13D for Soleno Therapeutics, Inc. |
05/09/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 8.2% stake in Reneo Pharmaceuticals, Inc. |
05/05/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/26/2023 |
8-K
| Quarterly results |
04/13/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 6.7% stake in Vera Therapeutics, Inc. |
04/13/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 3.4% stake in Exicure, Inc. |
03/28/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
03/22/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
03/22/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
03/09/2023 |
SC 13G
| Carlyle Group Inc. reports a 6.7% stake in Phathom Pharmaceuticals, Inc. |
02/27/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
02/23/2023 |
SC 13D/A
| Carlyle Group Inc. reports a 9.2% stake in Spruce Biosciences, Inc. |
02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
02/10/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|